Jaimiess Kit
Product Images NDC 70700-206

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Jaimiess (NDC 70700-206). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levonorgestrel And Ethinyl Estradiol Tablets 0.15mg/0.03 mg And Ethinyl Estradiol Tablets 0.01 mg Carton Label (Image 01)

Label for JAIMIESS extended-cycle kit containing levonorgestrel and ethinyl estradiol tablets with strengths 0.15 mg/0.03 mg and 0.01 mg. The kit includes 2 blister packs, each with 91 tablets. The label also shows the NDC number 70700-206 and the manufacturer Xiromed LLC.*

FDA Label Image

Figure 1: Likelihood Of Developing A Vte (Image 02)

A horizontal bar chart showing the number of women with a blood clot per 10,000 woman-years across four groups: Non-Pregnant Non-COC users, COC users, Pregnancy, and Postpartum (12 weeks only). The chart includes range values for each group, illustrating increasing risk from non-users to postpartum women, with detailed explanatory notes on pregnancy data assumptions.*

FDA Label Image

Figure 2. Percent Of Women Taking Levonorgestrel And Ethinyl Estradiol Tablets And Ethinyl Estradiol Tablets Who Reported Unscheduled Bleeding And/or Spotting Or Only Unscheduled Bleeding (Image 03)

A bar chart showing the percentage of subjects experiencing bleeding and/or spotting versus bleeding alone across four cycles of days in a study. Each cycle is split into periods of ≥7 days and ≥20 days, with percentages indicated for both bleeding and spotting combined and bleeding only, over specified day ranges and sample sizes (N).*

FDA Label Image

Figure 3: Relevant Studies Of Risk Of Breast Cancer With Combined Oral Contraceptives (Image 04)

A forest plot figure titled 'Relevant Studies of Risk of Breast Cancer with Combined Oral Contraceptives' showing effect estimates (odds ratio, relative risk, hazard ratio) with confidence intervals for various studies comparing breast cancer risk among ever users versus never users of combined oral contraceptives and current users versus never users. The horizontal axis represents effect estimates from -1.5 to 2.0, with study names and data points plotted accordingly.*

FDA Label Image

Levonorgestrel Structural Formula (Image 05)

Chemical structure of levonorgestrel illustrating its molecular framework. The image includes the chemical formula C21H28O2 and the molecular weight (MW) 312.4, representing the active ingredient levonorgestrel in the product JAIMIESS.*

FDA Label Image

Ethinyl Estradiol Structural Formula (Image 06)

Chemical structure of ethinyl estradiol, labeled with its molecular formula C20H24O2 and molecular weight 296.4, depicted as a steroidal compound with hydroxyl and alkyne functional groups.*

FDA Label Image

Figure 1, Patient Information (Image 07)

An illustration chart showing different methods of contraception ranked by pregnancy rates per 100 women in one year. It categorizes methods from fewer than 1 pregnancy to 85 or more pregnancies, listing implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal rings with hormones, condoms, diaphragm, abstinence during fertile days, spermicide, withdrawal, and no birth control.*

FDA Label Image

Figure 2, Instructions For Use (Image 08)

JAIMIESS kit containing levonorgestrel and ethinyl estradiol and ethinyl estradiol tablets, labeled by Xiromed LLC. The kit includes a weekly dosing chart with circular timers arranged in weeks, days marked from Sunday to Saturday, and spaces for lot number and expiration date. The image also shows the kit packaging with barcode and dosage information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.